-
Article
Open AccessNatural history of nonhuman primates after conjunctival exposure to Ebola virus
Transmission of Ebola virus (EBOV) primarily occurs via contact exposure of mucosal surfaces with infected body fluids. Historically, nonhuman primate (NHP) challenge studies have employed intramuscular (i.m.)...
-
Article
Open AccessCombination therapy protects macaques against advanced Marburg virus disease
Monoclonal antibodies (mAbs) and remdesivir, a small-molecule antiviral, are promising monotherapies for many viruses, including members of the genera Marburgvirus and Ebolavirus (family Filoviridae), and more re...
-
Article
Open AccessA single dose investigational subunit vaccine for human use against Nipah virus and Hendra virus
Nipah and Hendra viruses are highly pathogenic bat-borne paramyxoviruses recently included in the WHO Blueprint priority diseases list. A fully registered horse anti-Hendra virus subunit vaccine has been in us...
-
Article
Establishment of an African green monkey model for COVID-19 and protection against re-infection
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is responsible for an unprecedented global pandemic of COVID-19. Animal models are urgently needed to study the pathogenesis of COVID-19 and to scre...
-
Article
Open AccessIntranasal exposure of African green monkeys to SARS-CoV-2 results in acute phase pneumonia with shedding and lung injury still present in the early convalescence phase
We recently reported the development of the first African green monkey (AGM) model for COVID-19 based on a combined liquid intranasal (i.n.) and intratracheal (i.t.) exposure to severe acute respiratory syndro...
-
Article
Open AccessPrior vaccination with rVSV-ZEBOV does not interfere with but improves efficacy of postexposure antibody treatment
A replication-competent vesicular stomatitis virus vaccine expressing the Ebola virus (EBOV) glycoprotein (GP) (rVSV-ZEBOV) was successfully used during the 2013-16 EBOV epidemic. Additionally, chimeric and hu...
-
Article
Open AccessImmune correlates of postexposure vaccine protection against Marburg virus
Postexposure immunization can prevent disease and reduce transmission following pathogen exposure. The rapid immunostimulatory properties of recombinant vesicular stomatitis virus (rVSV)-based vaccines make th...
-
Article
Open AccessAuthor Correction: Infection with the Makona variant results in a delayed and distinct host immune response compared to previous Ebola virus variants
A correction to this article has been published and is linked from the HTML and PDF versions of this paper. The error has not been fixed in the paper.
-
Article
Human-monoclonal-antibody therapy protects nonhuman primates against advanced Lassa fever
Thomas Geisbert and colleagues show that a cocktail of monoclonal antibodies protects cynomolgus monkeys from lethal Lassa fever virus infection, including when administration is delayed by more than a week af...
-
Article
Open AccessInfection with the Makona variant results in a delayed and distinct host immune response compared to previous Ebola virus variants
Zaire Ebolavirus (ZEBOV) continues to pose a significant threat to human health as highlighted by the recent epidemic that originated in West Africa and the ongoing outbreak in the Democratic Rep...
-
Article
Rescue of non-human primates from advanced Sudan ebolavirus infection with lipid encapsulated siRNA
Although significant progress has been made in develo** therapeutics against Zaire ebolavirus, these therapies do not protect against other Ebola species such as Sudan ebolavirus (SUDV). Here, we describe an RN...
-
Article
Open AccessPathogenic Differences between Nipah Virus Bangladesh and Malaysia Strains in Primates: Implications for Antibody Therapy
Nipah virus (NiV) is a paramyxovirus that causes severe disease in humans and animals. There are two distinct strains of NiV, Malaysia (NiVM) and Bangladesh (NiVB). Differences in transmission patterns and mortal...
-
Article
Open AccessMost neutralizing human monoclonal antibodies target novel epitopes requiring both Lassa virus glycoprotein subunits
Lassa fever is a severe multisystem disease that often has haemorrhagic manifestations. The epitopes of the Lassa virus (LASV) surface glycoproteins recognized by naturally infected human hosts have not been i...
-
Article
Lipid nanoparticle siRNA treatment of Ebola-virus-Makona-infected nonhuman primates
Ebola-virus-targeting short interfering RNAs (siRNAs) encapsulated in lipid nanoparticles are adapted to the current outbreak strain of the virus, and the siRNA cocktail is shown to protect nonhuman primates f...
-
Article
Single-dose attenuated Vesiculovax vaccines protect primates against Ebola Makona virus
Two second-generation attenuated Ebola virus vaccines based on recombinant vesicular stomatitis virus protect macaques against infection with a recent Ebola virus isolate from Guinea.
-
Article
CD8+ cellular immunity mediates rAd5 vaccine protection against Ebola virus infection of nonhuman primates
Vaccines that protect nonhuman primates from lethal Ebola virus infection have been developed, but their protective mechanisms have not been clearly delineated. Nancy Sullivan et al. now report that the protectiv...
-
Article
Open AccessPathogenesis of lassa fever in cynomolgus macaques
Lassa virus (LASV) infection causes an acute and sometimes fatal hemorrhagic disease in humans and nonhuman primates; however, little is known about the development of Lassa fever. Here, we performed a pilot s...
-
Article
Live attenuated recombinant vaccine protects nonhuman primates against Ebola and Marburg viruses
Vaccines and therapies are urgently needed to address public health needs stemming from emerging pathogens and biological threat agents such as the filoviruses Ebola virus (EBOV) and Marburg virus (MARV). Here...
-
Article
Accelerated vaccination for Ebola virus haemorrhagic fever in non-human primates
Containment of highly lethal Ebola virus outbreaks poses a serious public health challenge. Although an experimental vaccine has successfully protected non-human primates against disease1, more than six months wa...
